A

Acclaro Medical

Sells cold-fiber fractional lasers for rejuvenation

Overview

Acclaro Medical provides the UltraClear Laser, a specialized aesthetic laser system designed for skin rejuvenation. It uses a cold fiber fractionated laser beam that creates tiny treated zones in the skin, reducing heat damage to surrounding tissue. This approach aims to stimulate collagen remodeling and improve issues like fine lines, wrinkles, sun and age spots, scars (including acne scars), and large pores. By delivering energy in small, controlled columns, the procedure minimizes pain and downtime while being suitable for most skin types. The company sells these laser devices to dermatologists, cosmetic surgeons, and medical spas, and it also earns revenue from ongoing maintenance and consumables. Compared with other aesthetic lasers, UltraClear emphasizes lower discomfort, shorter recovery, and strong safety and efficacy across diverse patients. The overall goal is to expand access to effective, safer skin rejuvenation with fast recovery in the global dermatology market.

Significant Headcount Growth

Work here?Claim your company

About Acclaro Medical

Simplify's Rating
Why Acclaro Medical is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

HardwareIndustrial & ManufacturingHealthcare

Company Size

51-200

Company Stage

Series B

Total Funding

$23M

Headquarters

Smithfield, RI

Founded

2018

Get referred to Acclaro Medical

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Acclaro promoted UltraClear at ASDS November 4-8, 2026, sustaining dermatologist mindshare.
  • AuraLux launched April 8, 2026, broadening product breadth and upsell opportunities.
  • FDA clearance in May 2024 supports reimbursement conversations and adoption across benign pigmentation clinics.

What critics are saying

  • All evidence comes from Acclaro press releases, signaling weak third-party validation versus Cynosure and Sciton.
  • A $23 million Series B from May 29, 2025 funds expansion, not durability.
  • If clinicians reject premium laser economics, Acclaro becomes a niche device vendor by 2027.

What makes Acclaro Medical unique

  • UltraClear remains the first 2910 nm cold ablative fiber laser, per Nov. 3, 2026.
  • AuraLux adds four modalities, letting clinicians treat pigmentation, wrinkles, scars, and prejuvenation.
  • Practice Development Managers embed with providers, tying hardware sales to workflow and patient-growth support.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$23M

Below

Industry Average

Funded Over

1 Rounds

Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.
Series B Funding Comparison
Below Average

Industry standards

$35M
$30M
$45M
$65M
$100M

Benefits

  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

21%

1 year growth

51%

2 year growth

46%
PR Newswire
Apr 8th, 2026
Acclaro Medical unveils AuraLux 2910 nm fiber laser for skin rejuvenation at AmSpa 2026

Acclaro Medical is showcasing its AuraLux 2910 nm Fiber Laser at the American MedSpa Association's annual meeting at Wynn Las Vegas from 9-12 April 2026. An evolution of the company's UltraClear platform, AuraLux delivers skin rejuvenation treatments safe for all skin types with minimal discomfort and faster recovery. The device offers four treatment modalities—3DMIRACL, REFRESH, RENEW and GLIDE—targeting concerns from pigmentation and fine lines to wrinkles and scars. Using CoolPulse technology, it deposits ultrafast micro pulses for greater comfort and noticeable results. Acclaro has introduced Practice Development Managers who work alongside providers to drive practice growth and patient care. Founded in 2018, the company focuses on developing aesthetic medical solutions emphasising safety and efficacy across all skin types.

PR Newswire
May 29th, 2025
Acclaro Medical Secures $23M Funding Round

Acclaro Medical has raised $23 million in Series B funding, led by Accelmed Partners with a $20 million investment and $3 million from 3E Bioventures Capital. This funding will support the growth of Acclaro's 2910 nm fiber laser technology, including products like UltraClear® and AuraLux™, and aid in global market expansion and new product development.

PR Newswire
Apr 10th, 2025
Acclaro Medical Introduces Auralux™ Fiber Laser: The Total Solution For Skin Health And Timeless Youth For All Aesthetic Providers And Patients

~ Next-Generation AuraLux Innovates Cold Fiber Laser Technology for Physician and MedSpa Practices Seeking Pioneering Preventative and Rejuvenation Treatments with Superior Safety, Less Discomfort and Minimal Downtime While Offering Practice Growth OpportunitiesSMITHFIELD, R.I., April 10, 2025 /PRNewswire/ -- Acclaro Medical today announced the launch of AuraLux™ cold fiber laser, an evolution of its successful 2910 nm laser technology, specifically developed as an exclusive treatment solution for total skin health and timeless youth across all aesthetic practices and patient demographics. AuraLux will be unveiled at The Medical Spa Show to be held at the Wynn Las Vegas on April 10-13, 2025, and hosted by the American MedSpa Association, a leading multi-faceted national organization for the medical spa industry

PR Newswire
May 14th, 2024
Acclaro Medical Announces Fda Clearance Of Ultraclear® Cold Ablative Fractional 2910 Nm Fiber Laser For Treatment Of Benign Pigmented Lesions And Vascular Dyschromia

"This clearance underpins our commitment to addressing the unmet needs of patients living with pigmentation disorders by improving upon the current treatment paradigm of acids, peels and passé devices," said Shlomo Assa, Co-Founder and President, Chief Technology Officer of Acclaro Medical. "Whether troubled by benign brown lesions or red discoloration, patients can now experience UltraClear's proven ability to rejuvenate their physical appearance with excellent results, reduced discomfort, minimal downtime and very limited risk.""Any change in skin tone can be concerning or upsetting," noted Dr. Erica Linnell, Founder MD of Linnell Dermatology and Aesthetics, Seattle, WA. "With the heightened awareness of skin cancer checks and an aging population, we have seen a corresponding rise in patient visits for evaluation and treatment of their pigmented lesions. The expanded regulatory indication for the UltraClear fiber laser now paves the way for us to resurface and make a difference in improving pigmentation issues with just one to two treatments."At the upcoming SCALE meeting in Nashville, TN, on May 16-19, 2024, key opinion leaders will showcase the effectiveness and versatility of UltraClear to treat a vast array of aesthetic skin conditions, ranging from the early signs of aging, facial wrinkles and crinkles around the eyes to unwanted pigmentation, the effects of gravity and scars, including acne, surgical and traumatic scars. By stimulating new cell growth leading to collagen and elastin remodeling, UltraClear treatment produces smoother and healthier-looking skin with minimal medical downtime

Yahoo Finance
Mar 29th, 2024
Ultraclear, The World'S First Cold Fiber Laser, Wins Major Beauty Award For "Best Laser Treatment For All Skin Tones" - Second Year In A Row

SMITHFIELD, R.I., March 29, 2024 /PRNewswire/ -- Acclaro Medical announced that its UltraClear® 2910 nm fiber laser was awarded the "Best Laser Treatment for All Skin Tones - 2024" from NewBeauty Magazine. The win in this highly regarded and very popular publication is a repeat favorite for the second year in a row, having secured the coveted award for UltraClear laser in 2023.The World's First Cold Fractional Ablative Fiber Laser (PRNewsfoto/Acclaro Medical Corporation)Helen Fang, Acclaro Medical's Chief Executive Officer, said, "We are thrilled to receive this prestigious 2024 NewBeauty honor and retain our leadership in the category of laser treatments for all skin types. "The award underscores UltraClear's exceptional commitment to advancing inclusivity in anti-aging care, notably by elevating safety and efficacy standards for patients with diverse skin tones, making these treatments accessible to a wider spectrum of individuals."UltraClear® is FDA-cleared and designed to successfully solve the most vital aesthetic needs of patients of all skin types, improving facial lines, wrinkles, sun damage, age spots, and scars with less pain and minimal to no downtime. The first high-speed, cold ablative 2910 nm fiber laser for total facial rejuvenation, UltraClear treats multiple skin layers—from stratum corneum to epidermis to mid dermis—to help reverse the signs of aging and effects of gravity. It vaporizes the outer layers of dull, damaged skin and heats the underlying skin layers with precisely controlled thermal energy. This causes the skin to heal and restructure, growing new skin cells and increasing collagen and elastin production

Recently Posted Jobs

Sign up to get curated job recommendations

Acclaro Medical is Hiring for 2 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs